Lupin Pharmaceuticals, Inc. (LPI)
has received final approval for its Ranolazine Extended release tablets, 500 mg
and 1,000 mg from the United States Food and Drugs Administration (FDA).
Ranolazine Extended release tablets are indicated for treatment of Chronic
angina. Friday, August 2, 2013
Epic Update : Lupin Pharmaceuticals
Lupin Pharmaceuticals, Inc. (LPI)
has received final approval for its Ranolazine Extended release tablets, 500 mg
and 1,000 mg from the United States Food and Drugs Administration (FDA).
Ranolazine Extended release tablets are indicated for treatment of Chronic
angina. 
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment